Literature DB >> 10314640

Tardive dyskinesia: update for the mental health administrator.

J E Kalachnik, K M Slaw.   

Abstract

In addition to the fact that TD is not dissipating and that short of a quality TD monitoring system the mental health administrator is rolling the dice regarding patient welfare and successful litigation, the administrator should be aware of several important auxillary issues. These issues are written informed consent (for the use of psychotropic medication) and minimal effective dose (for the psychotropic medication prescribed). It is likely the quality of a facility's practices and policy in these areas will come under scrutiny at some point, especially if TD is involved. The purpose of this article, therefore, is two-fold. The first is to update the administrator on TD and the related issues of informed consent and minimal effective dose. The second is to briefly outline applied policies the administrator may implement to address these issues. While the administrator will delegate the detailed development of such policies, it is critical he or she back such policies and be able to ascertain if the concepts and procedures incorporated serve the patient and protect the facility. Only then can the administrator delegate valuable monetary resources and properly exert effective personnel influence.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 10314640     DOI: 10.1007/bf02828455

Source DB:  PubMed          Journal:  J Ment Health Adm        ISSN: 0092-8623


  19 in total

1.  Right to refuse psychotropic medication: an interdisciplinary proposal.

Authors:  Franklin J Hickman; Phillip J Resnick; Kathryn B Olson
Journal:  Ment Disabil Law Rep       Date:  1982 Mar-Apr

2.  The prevalence of tardive dyskinesia in a mentally retarded population.

Authors:  M A Richardson; G Haugland; R Pass; T J Craig
Journal:  Psychopharmacol Bull       Date:  1986

3.  Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results.

Authors:  J E Kalachnik; S R Harder; P Kidd-Nielsen; E Errickson; M Doebler; R L Sprague
Journal:  Psychopharmacol Bull       Date:  1984

4.  The prevalence of tardive dyskinesia.

Authors:  J M Kane; M Woerner; J A Lieberman; P Weinhold; W Florio; M Rubinstein; J Rotrosen; J Kurucz; S Mukherjee; K Bergmann
Journal:  Psychopharmacol Bull       Date:  1985

5.  Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment.

Authors:  D E Casey; U J Povlsen; B Meidahl; J Gerlach
Journal:  Psychopharmacol Bull       Date:  1986

6.  High-dose versus low-dose strategies in the treatment of schizophrenia.

Authors:  J M Kane; A Rifkin; M Woerner; G Reardon; D Kreisman; R Blumenthal; M Borenstein
Journal:  Psychopharmacol Bull       Date:  1985

7.  Informing patients about tardive dyskinesia.

Authors:  M R Munetz; L H Roth
Journal:  Arch Gen Psychiatry       Date:  1985-09

8.  A tardive dyskinesia monitoring policy for applied facilities.

Authors:  J E Kalachnik; J G Larum; A Swanson
Journal:  Psychopharmacol Bull       Date:  1983

9.  Tardive dyskinesia in young mentally retarded individuals.

Authors:  C T Gualtieri; S R Schroeder; R E Hicks; D Quade
Journal:  Arch Gen Psychiatry       Date:  1986-04

10.  Costs and benefits of two doses of fluphenazine.

Authors:  S R Marder; T Van Putten; J Mintz; J McKenzie; M Lebell; G Faltico; P R May
Journal:  Arch Gen Psychiatry       Date:  1984-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.